Grape King Bio Ltd (1707.TW)
- Previous Close
135.00 - Open
135.00 - Bid 135.50 x --
- Ask 136.00 x --
- Day's Range
134.50 - 136.00 - 52 Week Range
127.00 - 163.50 - Volume
35,457 - Avg. Volume
183,900 - Market Cap (intraday)
20.147B - Beta (5Y Monthly) 0.48
- PE Ratio (TTM)
14.50 - EPS (TTM)
9.38 - Earnings Date Aug 11, 2025 - Aug 18, 2025
- Forward Dividend & Yield 6.90 (5.04%)
- Ex-Dividend Date Jun 23, 2025
- 1y Target Est
179.50
Grape King Bio Ltd, together with its subsidiaries, produces and sells pharmaceutical preparations, patent medicines, liquid tonics, drinks, and healthy food in Taiwan, China, and internationally. It operates through Multi-Level Marketing; Distributors; Original Design Manufacturer/Original Equipment Manufacturer; and Sales Channel segments. The company offers Chinese herbal medicines, probiotics, energy drinks, and health food supplements for gastrointestinal health, immunity regulation, female beauty, and health care. It also provides functional ingredients for intestinal care, weight control, liver care, brain health, eye care, feminine health, and sensual health care; and microbial fermentation, as well as food inspection services. In addition, the company offers health foods, beverages, cosmetics, and general and pet food. Grape King Bio Ltd was founded in 1969 and is headquartered in Taoyuan City, Taiwan.
www.grapeking.com.tw--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: 1707.TW
View MorePerformance Overview: 1707.TW
Trailing total returns as of 5/21/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 1707.TW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 1707.TW
View MoreValuation Measures
Market Cap
20.00B
Enterprise Value
16.29B
Trailing P/E
14.39
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.82
Price/Book (mrq)
2.07
Enterprise Value/Revenue
1.47
Enterprise Value/EBITDA
5.20
Financial Highlights
Profitability and Income Statement
Profit Margin
12.98%
Return on Assets (ttm)
10.13%
Return on Equity (ttm)
18.54%
Revenue (ttm)
11.16B
Net Income Avi to Common (ttm)
1.45B
Diluted EPS (ttm)
9.38
Balance Sheet and Cash Flow
Total Cash (mrq)
4.43B
Total Debt/Equity (mrq)
1.37%
Levered Free Cash Flow (ttm)
1.01B